Abstract 907P
Background
Adenoid cystic carcinoma (ACC) is characterized by multiple relapses and a poor prognosis. It is commonly considered a radioresistant tumor, indeed particle radiotherapy is especially indicated in ACC. Recently, ACC was stratified in two clusters with a different prognosis, ACC type I and II, according to distinct molecular features i.e. NOTCH activating mutation and TP63 upregulation, respectively. We aimed to disclose molecular profiles predictive of radiosensitivity or radioresistance features.
Methods
The study cohort comprised 54 patients with ACC of salivary gland origin, treated with surgery plus photon beam radiotherapy (R) or R alone. A survey in the literature yielded a list of 15 signatures including pan-cancer or different tumor-specific models (e.g. head and neck; breast cancer; glioblastoma; prostate cancer) with a total of 141 genes. The expression levels of these genes were retrieved and signatures scores were imputed following the methods described in the original papers. Log2-trasformed transcripts per million mapped reads values were retrieved from Ferrarotto et al. [PMC7854509]. Clinical and follow-up data were updated at 31st December 2022; overall survival (OS) as endpoint was estimated with the Kaplan-Meier method.
Results
Only the signatures developed on breast cancer gene-expression datasets among those investigated were able to stratify ACC patients; in particular, we focused on an immune-radiosensitivity signature [PMC8984882] able to reach HR=7.59, 95%CI 3.19-18.09, p=1e-07. The predicted radiosensitivity of this signature was significantly associated with ACC type II and lack of NOTCH mutations.
Conclusions
Molecular profile of ACC type II is significantly associated with an intrinsic radiosensitivity. The association of ACC radiosensitivity to breast cancer signatures warrants further research on the biology behind ACC and its molecular similarities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12